Latest Cystic fibrosis Stories
First Potential Drug to Treat Underlying Cause of Fatal Disease under Review by FDA BETHESDA, Md., Nov. 1, 2011 /PRNewswire-USNewswire/ -- For the first time, a drug that's designed to treat the underlying cause of cystic fibrosis, Kalydeco(TM) (ivacaftor), is under review by the U.S. Food and Drug Administration for possible approval in 2012. This milestone comes as the largest international gathering of cystic fibrosis experts kicks off in Anaheim, Calif., Nov. 3 - 5, 2011. Kalydeco...
A vampire-like bacteria that leeches onto specific other bacteria – including certain human pathogens – has the potential to serve as a living antibiotic for a range of infectious diseases, a new study indicates. The bacterium, Micavibrio aeruginosavorus, was discovered to inhabit wastewater nearly 30 years ago, but has not been extensively studied because it is difficult to culture and investigate using traditional microbiology techniques. However, biologists in the University of...
NEW YORK, Oct. 31, 2011 /PRNewswire/ -- The Children's Tumor Foundation, a non-profit organization dedicated to improving the health and well-being of millions of people living with neurofibromatosis (NF) and the leader in funding medical research to find treatments for the disorder, will host its 2011 Annual Benefit Dinner on Wednesday, November 2 in New York City to thank its supporters. This year the Children's Tumor Foundation will present the 2011 Children's Humanitarian Award to the...
ABBOTT PARK, Ill., Oct. 25, 2011 /PRNewswire/ -- Abbott (NYSE: ABT) today awarded $19,000 scholarships to two exceptional students - one undergraduate and one graduate - living with cystic fibrosis (CF). Lauren Meiss, winner of the Thriving Undergraduate Student Scholarship, and Emily Kramer-Golinkoff, winner of the Thriving Graduate Student Scholarship, were among 40 finalists living with CF who were eligible to receive the two scholarships through the CFCareForward program this year....
SYDNEY, Oct. 24, 2011 /PRNewswire/ -- Pharmaceutical company Pharmaxis (ASX: PXS) today announced the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a Marketing Authorisation for Bronchitol, clearing the way for the product to be used in Europe "for the treatment of cystic fibrosis in adults as an add-on therapy to best standard of care." Pharmaxis expects the European Commission to confirm this opinion and grant the...
New research in The FASEB Journal suggests that cigarette smoke interferes with the Cystic Fibrosis Transmembrane Conductance Regulator protein, leading to dry, sticky mucus and increased infections If you smoke cigarettes, you have more in common with someone who has cystic fibrosis than you think. A new research report appearing online in the FASEB Journal (http://www.fasebj.org) shows that smoking cigarettes affects the lungs in a way that is very similar to cystic fibrosis, a life...
Agile Sciences will collaborate with Dr. Richard Boucher, Director of the Cystic Fibrosis Center at the University of North Carolina, Chapel Hill Raleigh, NC (PRWEB) October 10, 2011 The National Institutes of Health (NIH) has awarded Agile Sciences a Phase I STTR Grant to evaluate the efficacy of Agile Sciences’ proprietary Agilyte™ anti-biofilm molecules for treating lung infections of cystic fibrosis patients. The molecules will be tested in a new model of chronic lung...
NEW ALBANY, Ohio, Sept. 26, 2011 /PRNewswire/ -- Save the date for October 8, 2011. That is when Commercial Vehicle Group, Inc, (CVG) will host it Second Annual Fall Car, Cycle and Truck Show. This year's event will be held at the CVG Corporate Headquarters, 7800 Walton Parkway, New Albany, OH, from 8:00 a.m. until 7:00 p.m. Proceeds from the show will benefit the Cystic Fibrosis Foundation of Central Ohio, as well as the Flying Horse Farms located in Mt. Gilead, OH. Last year's event...
Novartis donates 20,000 EURO to support the Cystic Fibrosis Worldwide Education program. In 2011 CFW will partner with thier member, CF Saudi Arabia to bring the first of its kind CF conference to the Middle East. (PRWEB) September 24, 2011 Novartis, a healthcare solutions company headquartered in Switzerland, has donated 20,000 EURO to Cystic Fibrosis Worldwide (CFW) education programs headed by Dr. Harry Heijerman. The Cystic Fibrosis Worldwide education team is comprised of seven top...
Surgery to correct gastroesophageal reflux disease, or GERD, can preserve lung function in patients with end-stage pulmonary disease both before and after transplantation, according to a new study from the University of Pittsburgh School of Medicine. The findings, published today in the Archives of Surgery, suggest that esophageal testing should be performed more frequently among these patients to determine if anti-reflux surgery is needed. Many end-stage lung disease patients,...
